AMP 2024 | Comprehensive Curated Content to Improve Detection and Reporting of Somatic and Germline Variants for WGS and Large Cancer Gene Panels

Dr. Mark Kiel is the co-founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. Mark received his MD/PhD in Clinical Pathology at the University of Michigan. He founded Genomenon to address the challenge of connecting researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cancer.

Cara has nearly 10 years of experience in clinical genomics, and has been contributing her expertise to interpretation of literature-based data related to genomic variants and targeted therapies in oncology and curation of those data into the Cancer Knowledgebase (CKB) since 2015. In addition to her curation-related activities, Cara regularly liaises with users to provide additional insights into the capabilities of CKB. She received her PhD from UCONN in genetics and genomics and has prior experience as a clinical research associate, and leverages her clinical and research expertise in her work on CKB, with the ultimate goal of enabling better patient outcomes.